Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD
Abstract Background The effect of biologic therapy on the incidence of inflammatory bowel disease (IBD)-related hospitalizations is controversial. The high efficacy of biologic agents is weighted against potential therapy-related adverse events, however, there are no data on the effect of biologic t...
Main Authors: | Gil Berkovitch, Shlomi Cohen, Ronit Lubetzky, Dana Singer, Anat Yerushalmy-Feler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | BMC Pediatrics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12887-021-02526-1 |
Similar Items
-
The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers?
by: Khalid Elmaghrawy, et al.
Published: (2021-01-01) -
Editorial: Microbiome in IBD: From Composition to Therapy
by: Ruixin Zhu, et al.
Published: (2021-06-01) -
Current status of IBD and surgery of Crohn's disease in Thailand
by: Woramin Riansuwan, et al.
Published: (2021-09-01) -
Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic
by: Khoon Lin Ling, et al.
Published: (2020-06-01) -
Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD
by: Amanda M Johnson, et al.
Published: (2021-01-01)